1-5 of 5
Xia Peng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation

Yuchen Jiang, Xia Peng, Yinchun Ji, Yang Dai, Yanfen Fang, Bing Xiong, Wenming Ren, Youhong Hu, Yi Chen, Jing Ai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (11): 2198–2206.
https://doi.org/10.1158/1535-7163.MCT-21-0127
Published: 01 November 2021
View article titled, The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G<sub>1</sub> Cell-Cycle Arrest through c-Myc Downregulation
Open the PDF for The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G<sub>1</sub> Cell-Cycle Arrest through c-Myc Downregulation in another window
Includes: Supplementary data
Journal Articles

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Xinyi Wang, Jing Ai, Hongyan Liu, Xia Peng, Hui Chen, Yi Chen, Yi Su, Aijun Shen, Xun Huang, Jian Ding, Meiyu Geng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 667–679.
https://doi.org/10.1158/1535-7163.MCT-18-0179
Published: 01 March 2019
View article titled, The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Open the PDF for The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Jing Ai, Yi Chen, Xia Peng, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkang Shen, Jian Ding, Meiyu Geng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (4): 751–762.
https://doi.org/10.1158/1535-7163.MCT-17-0368
Published: 01 April 2018
View article titled, Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Open the PDF for Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models in another window
Includes: Supplementary data
Journal Articles

Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.

Jing Ai, ZhengSheng Zhan, Ying Wang, Fang Chen, Xia Peng, Yi Chen, Yinchun Ji, Jian Ding, Meiyu Geng, Wenhu Duan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B285.
https://doi.org/10.1158/1535-7163.TARG-13-B285
Published: 01 November 2013
View article titled, Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.
Journal Articles

Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.

Zilan Song, Jing Ai, Zhiqing Liu, Xia Peng, Yi Chen, Jian Ding, Meiyu Geng, Ao Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B99.
https://doi.org/10.1158/1535-7163.TARG-13-B99
Published: 01 November 2013
View article titled, Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.